Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Respondent-driven sampling to recruit young adult non-medical users of pharmaceutical opioids: problems and solutions.

Daniulaityte R, Falck R, Li L, Nahhas RW, Carlson RG.

Drug Alcohol Depend. 2012 Feb 1;121(1-2):23-9. doi: 10.1016/j.drugalcdep.2011.08.005. Epub 2011 Aug 31.

2.

Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.

Johanson CE, Arfken CL, di Menza S, Schuster CR.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):190-5. doi: 10.1016/j.drugalcdep.2011.07.019. Epub 2011 Aug 21.

PMID:
21862241
3.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND.

J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.

4.

Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.

Lofwall MR, Wunsch MJ, Nuzzo PA, Walsh SL.

J Subst Abuse Treat. 2011 Oct;41(3):321-9. doi: 10.1016/j.jsat.2011.04.008. Epub 2011 Jun 12.

PMID:
21664789
5.

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Yokell MA, Zaller ND, Green TC, Rich JD.

Curr Drug Abuse Rev. 2011 Mar;4(1):28-41. Review.

6.

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L.

Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004. Epub 2010 Nov 27.

PMID:
21112758
7.

Post-marketing surveillance of methadone and buprenorphine in the United States.

Dasgupta N, Bailey EJ, Cicero T, Inciardi J, Parrino M, Rosenblum A, Dart RC.

Pain Med. 2010 Jul;11(7):1078-91. doi: 10.1111/j.1526-4637.2010.00877.x. Epub 2010 Jun 8.

PMID:
20545875
8.

Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers.

Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, Klinker L, Shaffer HJ.

J Subst Abuse Treat. 2010 Jul;39(1):41-50. doi: 10.1016/j.jsat.2010.03.014.

PMID:
20434868
9.

Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence.

Monte AA, Mandell T, Wilford BB, Tennyson J, Boyer EW.

J Addict Dis. 2009 Jul;28(3):226-31. doi: 10.1080/10550880903014767.

PMID:
20155591
10.

Indicators of buprenorphine and methadone use and abuse: what do we know?

Maxwell JC, McCance-Katz EF.

Am J Addict. 2010 Jan-Feb;19(1):73-88. doi: 10.1111/j.1521-0391.2009.00008.x. Review.

11.

Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Gwin Mitchell S, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhf A, Agar MH, O'Grady KE, Schwartz RP.

Am J Addict. 2009 Sep-Oct;18(5):346-55. doi: 10.3109/10550490903077820.

12.

Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population.

Martins SS, Storr CL, Zhu H, Chilcoat HD.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):58-67. doi: 10.1016/j.drugalcdep.2008.06.013. Epub 2008 Aug 15.

13.

Case series of buprenorphine injectors in Kuala Lumpur, Malaysia.

Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL.

Am J Drug Alcohol Abuse. 2008;34(4):511-7. doi: 10.1080/00952990802122259.

PMID:
18584580
14.

Use and misuse of buprenorphine in the management of opioid addiction.

Cicero TJ, Surratt HL, Inciardi J.

J Opioid Manag. 2007 Nov-Dec;3(6):302-8.

PMID:
18290581
15.

Methamphetamine use in Dayton, Ohio: preliminary findings from the Ohio Substance Abuse Monitoring Network.

Daniulaityte R, Carlson RG, Kenne DR.

J Psychoactive Drugs. 2007 Sep;39(3):211-21.

PMID:
18159774
16.

Correlates of nonmedical use of hydromorphone and hydrocodone:results from a national household survey.

Smith MY, Haddox JD, Di Marino ME.

J Pain Palliat Care Pharmacother. 2007;21(3):5-17.

PMID:
18032351
17.

Abuse of buprenorphine in the United States: 2003-2005.

Smith MY, Bailey JE, Woody GE, Kleber HD.

J Addict Dis. 2007;26(3):107-11.

PMID:
18018814
18.

Designer drug Subutex takes its toll in Tbilisi.

Parfitt T.

Lancet. 2006 Jul 22;368(9532):273-4. No abstract available.

PMID:
16869033
19.

Non-medical use of OxyContin Tablets in the United States.

Sees KL, Di Marino ME, Ruediger NK, Sweeney CT, Shiffman S.

J Pain Palliat Care Pharmacother. 2005;19(2):13-23.

PMID:
16061457
20.

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group.

Addiction. 2005 Aug;100(8):1090-100. Erratum in: Addiction. 2006 Sep;101(9):1374.

Supplemental Content

Support Center